Minibody for Conditioning prior to Hematopoietic Stem Cell and Progenitor Cell Transplantation
SARS-CoV-2 Pseudotyping Plasmids for Cutting-Edge Studies
NIAID scientists have developed plasmids that allow for production of pseudoviruses expressing SARS-CoV-2 spike protein. As SARS-CoV-2 is a lethal airborne virus, it must be handled in high-containment Biosafety Level 3 (BSL-3) laboratories that require strict airflow, ventilation and decontamination procedures.
SARS-CoV-2 Spike Fused to Hepatitis B Surface Antigen
The emergence of the SARS-CoV-2 virus and its immune-escaping variants have led to global COVID-19 pandemic/endemic, underscoring the urgent need for effective vaccines with strong and durable immune responses.
New Antimalarial Chemotypes Discovered Through Chemical Methodology and Library Development
Discovery of an imidazo[1,2-a]pyridines with Anticancer Properties
Discovery of an imidazo[1,2-a]pyridines with Anticancer Properties
Small Molecule Anti-cancer Agents that Stabilize the MYC-G-Quadruplex
The proto-oncogene c-Myc is deregulated and overexpressed in ~70% of all cancers. Thus, c-Myc is an attractive therapeutic target since disrupting c-Myc activity could be used as pan-chemotherapy. Beyond cancer, Myc is also a positive effector of tissue inflammation, and its function has been implicated in the pathophysiology of heart failure. Because c-Myc is a transcription factor, a rationally designed small molecule targeting c-Myc would be required to exhibit significant specificity.
Treatment of Periodontal Disease via ENPPI Inhibition
This technology focuses on enhancing cementum production, a key component in treating periodontal regression. The method involves inhibiting ectonucleotide pyrophosphatase phosphodiesterases (ENPP1), enzymes that play a significant role in mineralization processes. Pyrophosphate (PPi) is known to impede the growth of hydroxyapatite crystals, essential for mineralization. ENPP1 catalyzes the hydrolysis of ATP, generating PPi, which then hinders mineralization.